Thanks, Eric. Good afternoon, for call. thank and our you joining
on our we this to we at then actions up a and time to our at of over performance. for investments and believe strategic highlights the XXXX will the will some key financial more objectives the call year. on made and while turn Justin During we will and growth us quarter and I and expectations outlined detailed today's want for progress, XXXX also and call, look significant accelerate summary make the of plans provide progress financials guidance. fourth the a year, to set beyond. our XXXX I I We operational into sustain and beginning spend
X Bio-Rad new During new X,XXX with upwards XXXX, we Visium and of including litigation instruments, five FFPE. net sold drove our settled studies worldwide applications. XXX and products, We [indiscernible] launched Chromium
continued So XXXX X,XXX and placements. our X,XXX. was fueled more technologies nearly Cumulative to XX% scale organization. driven we the instrument peer-reviewed instruments These employees than the more revenue investments of papers continue million. $XXX contribute as growth in added to over to This new year, as growth of our sold bringing innovations increased prior and XX% XXX than to part year-over-year
and In XX% in approaches revenue cell Single essential gain increased discovery for addition, adoption spatial research. to XXXX. as consumables continue tools
the growth half growth Our about invest ahead, the continuing build will that high year. conviction and the our some opportunity as we're in and headwinds and in to of strong future. sustained notably opportunity to we while XXXX, temporarily And in drive ever, our as the impact remains most the company first we're bullish anticipate
$XXX million near-term of $XXX range offset to headwinds. existing For by This annual XXXX, XX% to with customers, growth. and following growth range be solid in representing to we million, revenues new the the expect XX% reflects
with First, the academic Omicron ongoing quarter, into first the of particularly impact customers.
our delayed look and has to XXXX beyond. this slowly we're development been we Second, more accelerating Xenium cohorts. than which and of platform, the the our other timing year transitory launches. of We recent product consumable somewhat third, momentum is throughout forward this on average, building cohorts have firmly customer into earlier utilization product ramping believe And
products X by X despite near the launched, quarter for me the instruments, million, go driven introduced totaled Once emerged XXXX saw results. year-over-year driven resonates up by customers early flexibility demand beyond plan year placement year, XX% The goes access user Chromium high throughput We to it Chromium encouraging on Chromium platform the we our again, headwinds cell the through has using our demand detail for on Series users. $XXX experiments and to of and appeal adopters. single scale this broad that platform powerful our most Omicron-related iX upgrades Before new drive available and which for for will instrument XX% existing want that recently continued base. to X customers fourth both enthusiasm sequentially, beyond. This analysis, we onboard is provide broader Revenue let this our and end Chromium across new and fourth customers to Since the our capabilities more for priorities, quarter we focus tools clear this Series. have that upgrade has of and/or quarter. we strong existing ensure solid with our to become why
Turning to consumables.
seeing far, we're more high growth applications. enable high or impractical HT cost-prohibitive exceeded and to launch, to scale using by are analyze and to customers significantly been Our samples the we their previously more kits Since up and encouraged so throughput studies our have in kits experiments. our cells throughput expectations have existing
We customer XXx help with and drive the of single all like leader our which are to experience, unique with our applications, because of cohorts. standard well cell and touch base. to Researchers covering proteins of expression, in customer new and growing great interest. have epigenetics, and offerings what made also is excellent our immune performance continues leadership saw customer multi-omics resonate consumables single breadth growth breadth this I'd cell across our on portfolio sustained fuel quarter. observing product of profiling, recent analysis of throughput continued gene The we
increasing do base fewer customers, owners. that not, and instrumental halo We own those types discussed an which of have have been Halo percentage average, instruments our previously consumables that on as that those two have customer we and to referred use users of are users.
adopters. do business the earlier than great customers it's because customers entering consumable points purchase for of emphasize I While who slower this single the it to want universe cohorts a an expanding the recent average, cohorts, utilization sign means that that similarly They instruments ecosystem. of still for the start cell of trajectory on grow ramping our are in ramping recent their long-term it franchise. of great earlier and consumable to a within long-term consistent the is usage This trajectory cohorts. utilization a because business are previous points Chromium level sign line growth with with sustainable our to
only customer saw strong and enthusiasm the very spatial life its it Turning both early doubled now Visium resolution revenue delivers QX FFPE. entire remains a frozen And fresh unbiased for progress. Visium. was XXXX. the analysis that while is at Visium in commercial across to high sample. and tissue platform in increasing cycle, we quarter
number quadrupled. the customers, In addition, important dedicated more signs of and to measures of number we the XXx the limited by preprints of future tissue XXX success Visium clear All support resonating company with of investments almost added And made nearly our input, of with the than growth. are R&D peer-reviewed indicators leading commercial in entirely XXXX, anticipation of researchers are significant doubled employees having market these we nearly customers. hires the new while the team majority are finally, driven Notably, specialists. our these are team, demonstrating of of In to Both the adoption. including benefits Visium our that these these organizations in scale the with publications are during using Visium. papers year, with
global also sites open off our manufacturing to We Sweden the at in R&D expect our grew Singapore expansion and we sophisticated footprint, year-end. our by and California, scaling which headquarters in of kicking facilities Pleasanton,
technologies. the first This of published measures that one that best new XXXX. is to papers, said always than bringing our have the year, the total We in customers discoveries the our with impact since publication make more X,XXX our X,XXX of over peer-reviewed customers
moved to products, exploratory increasingly studies featuring translational As gained beyond mainstream research studies more disease-oriented these breakthroughs attention. and our
Times curing neurodegenerative CNN The showcased cell understanding the with and a revolutionize on recently, patients COVID the of foundational long York CAR-Ts disease. outfield a research highlighted of featured cycle our human Just step to motor centers leukemia. cortex, on New
drive continuing future. Chromium, growth conviction continued starts a opportunity in unwavering, we high look our the we're in and As ahead, significant and build platforms: This complementary three our company Xenium. on to our to Visium is investments with
operations continue Starting of with these our future. in and development. product to support and will the to R&D the invest platforms in success We commercial team also capabilities
excited very that products year's new this product increased of of First, our enable platform. we areas: key are two pipeline, and about We around Visium; which situ Xenium Chromium have the adoption acceleration prioritized in second, and
we're this analysis, while is in cell First very with opportunity the optimistic early a trajectory. this about still single in Chromium, very well-established now long-term leader platform and
is make every make Our analysis research. most lab biological it biology the for standard to the to accessible in to cell goal world single
the a human kit, potential choosing. many around from collection our for are to place bottlenecks new translational profiling fix imposes to year. at drive collection, transformative of our be are to their cell and mind, invest We their when fixed RNA to tissue long create working essential single critical single single-cell customers. a experiments for will franchise of This workflows. store the through need in viability addresses and to samples, broad their our plan profiling significant later continue our workflow With it We this more burden and be researchers processing cell instrument. difficult time really which customers intricately and at now proceeding This remove researchers maintain over to customers, cell has believe to our our it's value this term. adoption, in kit must with the particularly we this a excited With launch RNA the product to sample time on fixed to our of their Chromium on able will product world. Today,
profiling efficient genes Series workflow to relevant intend to We this built-in in to efficient focus the on X benefits, on to mid-XXXX. launch to kit exclusively the most capabilities sample product RNA targeting improved the delivers more addition multiplexing sequencing, research. and their In Chromium and also enable fixed sensitivity customers
or to and discovery. their potential the back and up researchers Enabled B with in half new to binding of to profiling at the exponentially top the antibody antigen resolution, We of transform also has determine our By and look cells virtue the built analyze BEAM millions The planned BEAM scale the of Antigen Barcode to T plex forward cell T of will process or high launch product is of on Mapping our solution allow product, resolution. year. new to high
Now on Visium. to
road in discovery of spatial research. continue believe on breadth our invest aggressively to advance series more anticipate We business spatial and robust samples more starting resolution. focused the of launches to we in mid-XXXX, leadership our in more analytics, enabling the and map unrivaled is We analysis,
the high-plex on First, tissue. enable protein we'll same simultaneous expression analysis gene and
tissues. more We larger will workflow create these customer ship support catching and add for them customers capabilities improved We additional will believe our also to for an expect and and flexibility value mid-XXXX. for areas significant to in access
of much and will platform represent the entire to HD. single Second, across ship to simplify customers higher entire to of instrument it really resolution research, will end to expect which Visium finally, at will believe discovery the the we Visium forward HD the our cell the XXXX. scale. single samples expand access ability sample near to best plan transcriptome spatial looking the product significantly number Visium giving back CytAssist tissue for We of and with the we launch the accessible we're And the half tissue platform. the year, to workflow in go this
and focused incredible analyze and It a the building deeply high platform in from at complementary their the across measure specific in Xenium Lastly, know customers will Chromium of Xenium both high sample. help workflow. to our robust detail a that provide with the by throughput. We're on they're customers level insight means naturally for to up, plex once is helps looking genes characterizing tissue platforms validating high works pads platform fully Visium. providing Xenium tissues, integrated turning an for. sample following situ to the for build issues It they ability and resolution these and on directly at analysis. what targets will
researchers. by standard that As the we goal the make expansion We our industry anticipate platforms customer our to integration particularly be is application have to rapid will three experience. Xenium and innovation, pursuing of excellent experience customer across valuable done previously, the
We from space Since the announced clinical and analysis tissue been a have enter opportunity long to practice. and research customers. plans with that transform of CartaNA to ReadCoor, acquisitions science represents tremendous believed interest life we tremendous there's with ultimately, in our potential our
we with course and of our believe we on than innovations. opportunity faster progress the own resources the robust shifted planned. can together materialized interest access have XXXX, opportunity technology previously we earlier intellectual acquired with than our At progress and and anticipated. situ to initially we in Based property the time, Xenium, Over same made intentionally building we this our our the - and we've we prioritized from on own customers, significant
situ additional We lines. resources time invested have to accelerate prioritize in our
Xenium As year. to plan we of this instruments a result, by end ship the
launch While we're this new products new our than strategy. confident in somewhat - our planned, that later will we some initially of
our Here, XXx, will as the and us in prioritizing days earlier been we That the guide has philosophy our decisions, forward. of moving all continue long-term are view. to since
I Before over the it. positioned and I strong Justin, call as as turn vast want our is ever, clear, on we're be opportunity to the ahead to to well conviction achieve
drives using and analyzed we not vision technologies mission, medicine. I will more the of on over know the future and make With investments our make That's our ahead that, the of strategy vast financials. the turn While our platforms. we fulfill foundation tissue be in now biggest three transform to how building. the we Justin detail future, health we're may for need our the impact innovate majority call to the samples will linear, across our That path continue be In will what as is. the to endpoint and
